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Pain is a complex, multidimensional experience but often is measured as a unidimensional experience. ,is study aimed to
separately assess the sensory and affective components of pain and identify their relations to important pain-related outcomes,
particularly in terms of opioid misuse risk and emotion dysregulation among patients with chronic pain receiving treatment in
Appalachia. Two hundred and twelve patients presenting to a multidisciplinary pain center completed the Difficulties in Emotion
Regulation Scale (DERS-18), Screener and Opioid Assessment for Patients with Pain—Revised (SOAPP-R), and short-form
McGill Pain Questionnaire (SF-MPQ).,e sensory experience of pain was unrelated to emotion dysregulation (r� 0.06, p � 0.57)
and weakly related to opioid misuse risk (r� 0.182, p< 0.05). In contrast, the affective experience of pain was moderately related to
emotion dysregulation (r� 0.217, p< 0.05) and strongly related to opioid misuse risk (r� 0.37, p< 0.01). In addition, emotion
dysregulation predicted variance in opioid misuse risk above and beyond the affective and sensory experiences of pain ((b� 0.693,
p< 0.001). ,e results suggest patients with a strong affective experience versus sensory experience of pain and challenges with
emotion regulation may require a more comprehensive intervention to address these underlying components in order to reduce
their risk of misusing opioid medications.
1. Introduction
Chronic pain is understood to be a complex biopsychosocial
experience [1]; however, measurement of pain in many
clinical settings fails to differentiate between these symptom
domains. Instead, pain is reduced to a primarily sensory
event of varying intensity. Failure to recognize and address
this complexity contributes to a myriad of problems asso-
ciated with chronic pain, from untreated pain-related dis-
tress to more macroconcerns, such as the opioid epidemic
[2]. To remedy this issue, pain researchers across disciplines,
including Ballantyne and Sullivan [3], have proposed uti-
lizing multiple measures of pain-related factors to clarify a
person’s pain experience and to further inform possible
multimodal treatments for chronic pain. Measuring pa-
tients’ chronic pain experience requires assessment that
acknowledges the various qualitative differences in pain and
goes beyond simple pain severity [4–6]. Patients also report
that a numeric rating scale alone does not capture their
subjective experience of pain despite its common use in
medical settings [7].
When asked to quantify pain intensity, the validity of
numerical scales is impacted by patient’s inclusion of other
concurrent sensations and experiences rather than simply
pain intensity [8]. In fairness, it is difficult for patients to
tease apart pain severity from the other aspects of pain that
contribute to its discomfort in a single question. In addition,
recent research suggests the three most common measures
used to assess pain intensity (i.e., Visual Analog Scale,
Numeric Rating Scale, and Pain Severity Subscale of the Brief
Pain Inventory) demonstrate low- to very low-quality evi-
dence of content validity, thus not providing particularly
useful information to researchers and clinicians [9]. Alter-
natively, as an example, the McGill Pain Questionnaire
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(MPQ) and its short form (SF-MPQ) are widely used to
assess both the sensory and affective components of pain,
with an emphasis on the unique quality of the pain expe-
rience [10, 11]. Assessing these components offers critical
information regarding the perceptual qualities of pain [4]
and provides valuable insight into the patient’s pain expe-
rience beyond the severity and duration of their pain. By
including more comprehensive assessment of pain factors,
the barriers to pain relief are more easily elucidated and
appropriate treatment can be offered.
When addressing barriers to pain relief, emotion reg-
ulation issues may be overlooked, particularly in a tradi-
tional medical setting; however, these issues can significantly
complicate a patient’s ability to manage chronic pain and
pain itself may lead to poorer emotion regulation. ,e ex-
perience of chronic pain is further complicated by the likely
difficulty in regulation of affect associated with this chronic
stressor. For example, suffering from chronic pain may
present as a constant stressor that increases the amount of
negative affect one experiences and thus it might become
increasingly difficult for one to regulate their emotions [12].
Emotion dysregulation is defined as the absence of aware-
ness and lack of acceptance of one’s emotions, the inability to
change emotions in accordance with one’s goals, and the
inability to control behavior in the face of negative emotions
[13]. Like all coping strategies, there are positive/healthy and
negative/unhealthy approaches to emotion regulation.
Positive or healthy emotion regulation approaches include
skills such as cognitive reappraisal, mindfulness, acceptance,
and problem solving. Negative or unhealthy emotion reg-
ulation approaches include self-injury, avoidance, and
substance misuse, and while these may be effective tem-
porarily, they often lead to more problems. ,is point is
supported by the fear-avoidance model of chronic pain,
which outlines the ways in which emotion, fear specifically,
can promote avoidance which in turn perpetuates disability
and fear [14]. Emotion dysregulation in patients with
chronic pain may lead to difficulty in accurately assessing
pain intensity and other pain factors, negatively impacting
pain perception [7–9]. Emotion dysregulation is associated
with modifying experiences of pain. Ruiz-Aranda et al. [15]
found that women with the emotion regulation strategy of
emotional repair (i.e., attenuate to and value feelings, clarity
about feelings, and utilization of positive thinking to repair
negative moods) reported having less pain during an ex-
perimental pain induction. A lack of emotion regulation
plays a role in the increase in negative affect and dysfunc-
tional beliefs related to pain [16], while regulation of positive
and negative affect predicts greater decreases in pain [17].
Hamilton et al. [18] also found the magnitude of pain re-
activity varied as a function of both emotional intensity and
ability to regulate emotion. ,us, evaluating emotion reg-
ulation abilities in patients with chronic pain may be helpful
in understanding difficulties in managing pain and exac-
erbations in pain symptoms.
Examining emotion dysregulation more specifically in
the chronic pain population reveals a link with opioid
misuse risk and poor health-related outcomes [19, 20].
Furthermore, opioid misuse is independently associated
with both chronic pain experience [21] and emotion dys-
regulation [22]. ,us, it is entirely possible that individuals
who experience chronic pain may rely upon opioid medi-
cations in order to assist in emotion regulation. Garland
et al. [21] noted that, in addition to attenuating the sensory
aspects of pain, opioids may ameliorate the affective pain
experience or patient’s perception of pain. When uncon-
trolled use of opioids couples with chronic pain, there is
dysregulation in the reward-processing center of the brain,
which suggests that the affective experience of pain may
drive the enduring and relapsing nature of substance use
disorder, due to the way in which opioid medication
stimulates this area of the brain [23]. ,is research suggests
that although opioids are prescribed with the goal of alle-
viating nociceptive pain, or the sensory experience of pain,
individuals may continue using opioid medication or mis-
using it due to its affective or emotional effects (i.e., an
unhealthy emotion regulation strategy for chronic pain).
Because of the potential misuse of prescribed opioid med-
ication and its addictive properties, it is important to identify
risk factors for misuse prior to prescribing [24, 25].
To date, limited research has investigated the affective
and sensory experiences of chronic pain and their relation
with opioid misuse and emotion dysregulation. ,e current
study aims to examine pain as an affective and sensory
experience, as measured by the SF-MPQ to identify asso-
ciations between these pain experiences, opioid misuse risk,
and emotion dysregulation, as well as to identify the factors
that contribute to variance in opioid misuse risk to identify
target areas of treatment in future research. ,e authors
propose four hypotheses related to this study: (1) in support
of prior findings, the affective experience of pain will be
associated with opioid misuse risk; (2) given the previous
associations identified between affect and opioid misuse, as
well as pain and emotion dysregulation, emotion dysregu-
lation will be associated with opioid misuse risk; (3) based
upon prior research identifying emotional and affective
components of pain as integral to opioid misuse, the sensory
experience of pain will be unassociated with opioid misuse
risk and emotion dysregulation; (4) lastly, given prior re-
search, the affective experience of pain will predict variance
in opioid misuse risk above and beyond the sensory expe-
rience of pain or emotion dysregulation.
2. Materials and Methods
,is sample was part of a larger database from a previous
study examining pain-related outcomes [26]. A sample of
212 patients with chronic pain presented to a multidisci-
plinary pain center at West Virginia University on referral
from pain center physicians (52.8% female, mean age� 53.6,
SD� 10.8). Patients participated in a psychological interview
and completed a series of standardized measures as part of
an evaluation to assess for risk of opioid misuse.
2.1. Measures
2.1.1. Demographic Information. Data on patients’ age, sex,
education, duration of pain, and location of pain were
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gathered via self-report questionnaires (see Table 1 for
demographics).
2.1.2. Difficulties in Emotion Regulation Scale-18 (DERS-18).
,e DERS-18 is a short-form version of the 36-item self-
report measure of emotion dysregulation [13, 27]. Items
are rated from 1 (“almost never”) to 5 (“almost always”),
and some items are reverse coded. Higher scores indicate
greater difficulty in emotion regulation. ,e scale consists
of six subscales measuring differing types of difficulty in
emotion regulation and demonstrates good reliability,
internal consistency, and convergent validity, as well as
concurrent validity with the original DERS [13]. None of
the subscales of the DERS-18 were analyzed and solely
total scores were utilized in this study due to the study’s
focus on general levels of emotional dysregulation in
association with pain experience. Total scores range from
18 to 90, with greater scores indicating greater emotion
dysregulation (i.e., poorer emotion regulation skills). ,e
DERS-18 has an overall Cronbach’s alpha of .91 [13]. ,e
DERS-18 also demonstrated strong predictive validity in a
diary study and strong concurrent validity with the
original DERS scale [13].
2.1.3. Short-Form McGill Pain Questionnaire (SF-MPQ).
,e SF-MPQ is an abbreviated version of the McGill Pain
Questionnaire [11], and it measures quality of pain [28]
that utilizes 11 sensory descriptors and four affective
descriptors (4) [11]. Items are rated by respondents from 0
(none) to 3 (severe). Scores range from 0 to 33 (Sensory
Subscale) and 0 to 12 (Affective Subscale) with higher
scores indicative of greater pain severity along with
greater number of descriptors.,e SF-MPQ also exhibited
good sensitivity to change following chronic pain treat-
ment [11]. ,e SF-MPQ demonstrated strong validity via
significant correlations between subscale and total scores
for the short form and long form [11].
2.1.4. Screener and Opioid Assessment for Patients with
Pain—Revised (SOAPP-R). ,e SOAPP-R is a self-report
measure that assesses risk for misuse of opioid medication
[29]. ,e 24-item measure asks respondents to rate the
frequency of occurrence using a Likert scale that ranges from
0 (“never”) to 4 (“very often”). Total scores range from 0 to
96, with higher scores indicating higher risk for opioid
misuse. If the score is ≥18, this indicates high risk for opioid
misuse. Good internal reliability, specificity, and sensitivity
are demonstrated when using the SOAPP-R to identify those
at elevated risk for opioid misuse [29]. Test-retest intraclass
correlations for the total scale were 0.92. In addition,
Cohen’s d effect sizes were calculated for each item, and all
were above 0.40 indicating strong predictive validity [29].
Cronbach’s alpha for the total score was 0.88 demonstrating
strong internal reliability [29].
3. Results and Discussion
To investigate the first three hypotheses, Pearson R correla-
tions were calculated for the variables of interest (see Table 2).
Correlations are interpreted such that a correlation of r� 0.1-
0.2 is considered small, r� 0.2-0.3 is considered medium, and
anything above r� 0.3 is considered large or strongly related
[30]. ,e sensory and affective components of pain were
uniquely related to the pain-related outcomes of opioidmisuse
risk and emotion dysregulation. In support of prior research
and hypotheses, the affective experience of pain was strongly
related to opioid misuse risk (r� 0.37, p< 0.01) and moder-
ately related to emotion dysregulation (r� 0.217, p< 0.05).
Contrary to hypotheses, the sensory experience of pain was
related, though weakly, to opioid misuse risk (r� 0.182,
p< 0.05), though unrelated to emotion dysregulation (r� 0.06,
p � 0.57). For all correlations, see Table 2.
To investigate the fourth hypothesis, a multiple linear
regression was conducted. Independent variables in-
cluded the affective experience of pain, sensory experience
of pain, and emotion dysregulation. ,e overall model
significantly predicted variance in opioid misuse risk
(R � 0.75, R2 � 0.57, F (3, 70) � 29.07, p< 0.001). Inter-
estingly, and contrary to hypotheses, emotion dysregu-
lation was the only predictor that emerged significant in
the model (b � 0.693, p< 0.001), despite the prior asso-
ciations between affective experience of pain and emotion
dysregulation. Based upon Ferguson’s [31] guidance on
effect size in social science, this effect produced a medium
effect size. For regression results, see Table 3.
Patients with a higher affective experience of pain may
be at increased risk for emotion dysregulation or opioid
misuse relative to those who have a stronger sensory
experience of pain. Pain patients should routinely be
interviewed about the nature of their pain and both bi-
ological and psychological factors that contribute to their
experience. In support of these findings, recent research
has identified emotional dysregulation as a key compo-
nent of opioid misuse and suicidality in chronic pain
patients [32]. ,e results of this study suggest that
emotional dysregulation also plays a key role in opioid
misuse risk, above and beyond the affective or sensory
experiences of pain. ,us, future research may address
Table 1: Demographic information.
Variable Mean SD Frequency (%)
1. Age (years) 53.59 10.82 —
2. Education (years) 12.59 2.5 —
3. Pain duration (years) 12.32 10.18 —
4. Pain location (percent yes)
Neck — — 41.60
Low back — — 83.80
Upper extremities — — 29.60
Lower extremities — — 61.40
Others — — 54.80
Percentages are each out of 100%, as participants often indicated multiple
locations of pain.
Pain Research and Management 3
how emotion dysregulation might be assessed or ame-
liorated in chronic pain patients prior to or concurrent
with opioid treatment.
,e study was limited in that it was correlational in
nature; however, these findings have interesting impli-
cations for the treatment and future study of the biop-
sychosocial nature of pain and co-occurring substance use
disorder. In addition, given that this study was cross-
sectional in nature, no conclusions about the direction-
ality of the relation identified in the multiple linear re-
gression may be made. ,is study also relied upon self-
report of all variables. Future studies might utilize more
objective measures or indicators of pain or opioid use
(rather than risk) in order to obtain multiple reports. To
that point, it is imperative that future research addresses
the biological portion of the biopsychosocial model in the
relation between pain experience and opioid misuse and
risk. It is entirely possible that endogenous opioids or
genetic influence may have an impact on the relations
identified in this study. Our results suggest that future
research should investigate the possibility of a causal
relation between the affective experiences of pain and
opioid misuse and emotion dysregulation and potential
nonopioid treatments for patients with a highly affective
pain experience.
4. Conclusion
,is study highlights the importance of assessing for pain
experience and possible biological and psychological factors
that contribute to chronic pain patients’ experience. ,e
sensory experience of pain was weakly associated with
opioid misuse risk, but unrelated to emotion dysregulation.
,e affective experience of pain was related to opioid misuse
risk and emotion dysregulation. Further research is needed
to investigate a causal relationship between the affective and
sensory experiences of pain, opioid misuse, and emotion
dysregulation.
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